210 related articles for article (PubMed ID: 22460617)
1. Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer.
Kamal AH; Camacho F; Anderson R; Wei W; Balkrishnan R; Kimmick G
Breast Cancer Res Treat; 2012 Jul; 134(1):371-8. PubMed ID: 22460617
[TBL] [Abstract][Full Text] [Related]
2. Cost impact of oral capecitabine compared to intravenous taxane-based chemotherapy in first-line metastatic breast cancer.
Camacho FT; Wu J; Wei W; Kimmick G; Anderson RT; Balkrishnan R
J Med Econ; 2009 Sep; 12(3):238-45. PubMed ID: 19732030
[TBL] [Abstract][Full Text] [Related]
3. Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer.
Blum JL; Barrios CH; Feldman N; Verma S; McKenna EF; Lee LF; Scotto N; Gralow J
Breast Cancer Res Treat; 2012 Dec; 136(3):777-88. PubMed ID: 23104222
[TBL] [Abstract][Full Text] [Related]
4. Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors.
Gilabert M; Bertucci F; Esterni B; Madroszyk A; Tarpin C; Jacquemier J; Extra JM; Viens P; Gonçalves A
Anticancer Res; 2011 Mar; 31(3):1079-86. PubMed ID: 21498742
[TBL] [Abstract][Full Text] [Related]
5. Thymidylate synthase and thymidine phosphorylase as predictive markers of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
Lee SJ; Choi YL; Park YH; Kim ST; Cho EY; Ahn JS; Im YH
Cancer Chemother Pharmacol; 2011 Sep; 68(3):743-51. PubMed ID: 21170649
[TBL] [Abstract][Full Text] [Related]
6. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes.
Hortobagyi GN; Gomez HL; Li RK; Chung HC; Fein LE; Chan VF; Jassem J; Lerzo GL; Pivot XB; Hurtado de Mendoza F; Xu B; Vahdat LT; Peck RA; Mukhopadhyay P; Roché HH
Breast Cancer Res Treat; 2010 Jul; 122(2):409-18. PubMed ID: 20454927
[TBL] [Abstract][Full Text] [Related]
7. Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy.
Clemons M; Joy AA; Abdulnabi R; Kotliar M; Lynch J; Jordaan JP; Iscoe N; Gelmon K
Breast Cancer Res Treat; 2010 Nov; 124(1):177-86. PubMed ID: 20814815
[TBL] [Abstract][Full Text] [Related]
8. Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational?
Zhang J; Gu SY; Gan Y; Wang ZH; Wang BY; Guo HY; Wang JL; Wang LP; Zhao XM; Hu XC
Cancer Chemother Pharmacol; 2013 Jan; 71(1):103-13. PubMed ID: 23053266
[TBL] [Abstract][Full Text] [Related]
9. Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer.
Huang H; Jiang Z; Wang T; Zhang S; Bian L; Cao Y; Wu S; Song S
Anticancer Drugs; 2012 Aug; 23(7):718-23. PubMed ID: 22739713
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Paija O; Helle L; Villman K; Nyandoto P; Nilsson G; Pajunen M; Asola R; Poikonen P; Leinonen M; Kataja V; Bono P; Lindman H
J Clin Oncol; 2012 Jan; 30(1):11-8. PubMed ID: 22105826
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer.
Babacan T; Efe O; Hasirci AS; Demirci F; Buyukhatipoglu H; Balakan O; Sarici F; Kertmen N; Esin E; Akin S; Ates O; Aksoy S; Sever AR; Altundag K
Tumori; 2015; 101(4):418-23. PubMed ID: 25953439
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer.
Blum JL; Dees EC; Chacko A; Doane L; Ethirajan S; Hopkins J; McMahon R; Merten S; Negron A; Neubauer M; Ilegbodu D; Boehm KA; Asmar L; O'Shaughnessy JA
J Clin Oncol; 2006 Sep; 24(27):4384-90. PubMed ID: 16926223
[TBL] [Abstract][Full Text] [Related]
13. Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer.
Leonard R; Hennessy BT; Blum JL; O'Shaughnessy J
Clin Breast Cancer; 2011 Dec; 11(6):349-56. PubMed ID: 21856245
[TBL] [Abstract][Full Text] [Related]
14. First-line capecitabine monotherapy for slowly progressing metastatic breast cancer: do we need aggressive treatment?
Debled M; Madranges N; Trainaud A; Floquet A; Donamaria C; Brouste V; Durand M; Mauriac L
Oncology; 2009; 77(5):318-27. PubMed ID: 19940523
[TBL] [Abstract][Full Text] [Related]
15. Moderate dose capecitabine in older patients with metastatic breast cancer: a standard option for first line treatment?
Kotsori AA; Noble JL; Ashley S; Johnston S; Smith IE
Breast; 2010 Oct; 19(5):377-81. PubMed ID: 20392643
[TBL] [Abstract][Full Text] [Related]
16. Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study.
Gradishar WJ; Meza LA; Amin B; Samid D; Hill T; Chen YM; Lower EE; Marcom PK
J Clin Oncol; 2004 Jun; 22(12):2321-7. PubMed ID: 15197193
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy for metastatic breast cancer. Comparison of clinical practice and cost of drugs in two cohorts of patients: 1994-1998 and 2003-2006.
Galy G; Labidi-Galy SI; Perol D; Bachelot T; Ray-Coquard I; Tredan O; Biron P; Latour JF; Blay JY; Guastalla JP; Favier B
Breast Cancer Res Treat; 2011 Jul; 128(1):187-95. PubMed ID: 21184270
[TBL] [Abstract][Full Text] [Related]
19. A Phase II trial of split, low-dose docetaxel and low-dose capecitabine: a tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer.
Silva O; Lopes G; Morgenzstern D; Lobo C; Doliny P; Santos E; Abdullah S; Gautam U; Reis I; Welsh C; Slingerland J; Hurley J; Gluck S
Clin Breast Cancer; 2008 Apr; 8(2):162-7. PubMed ID: 18621613
[TBL] [Abstract][Full Text] [Related]
20. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.
Robert NJ; Diéras V; Glaspy J; Brufsky AM; Bondarenko I; Lipatov ON; Perez EA; Yardley DA; Chan SY; Zhou X; Phan SC; O'Shaughnessy J
J Clin Oncol; 2011 Apr; 29(10):1252-60. PubMed ID: 21383283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
